360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Threshold Pharmaceuticals Inc

Type: Company

Name: Threshold Pharmaceuticals Inc

Nationality: United States

Web Address: http://www.thresholdpharm.com/

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Threshold Pharmaceuticals Earnings Review: 17 Days after Announcement Shares Up 21.1% (THLD)

(Comtex SmarTrend(R)) When Threshold Pharmaceuticals (NASDAQ:THLD) reported earnings two weeks ago on May 3rd, 2013, analysts, on average, expected the company to report a loss of $0.10 on sales of $2.8 million. Threshold Pharmaceuticals actually reported ... [Published Individual.com - May 20 2013]

Entities: Threshold Pharmaceuticals Inc, Stocks, Comtex

First reported May 18 2013 - Updated May 18 2013 - 1 reports

A Journey To Add Biotech To The Portfolio

I recently evaluated my portfolio and realized I was completely invested in companies with market capitalizations over $100 billion. With what looks like a recovery to the overall economy of the US, I wanted to reallocate some of my portfolio to gain ... [Published Seeking Alpha - May 18 2013]

Entities: Biotechnology, Portfolio, NeuVax

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Threshold Pharmaceuticals Inc

Threshold Pharmaceuticals Shares Climbing Higher, Up 3.2%

(Financial News Network On) Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's biggest movers, up 3.2% to $5.47. The Dow is up 0.4% to 15,296 and the S&P is currently up 0.5% to 1,659. Threshold Pharmaceuticals Inc. is a biotechnology company ... [Published Individual.com - May 17 2013]

Entities: Threshold Pharmaceuticals Inc, Stocks, Biotechnology

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Threshold Pharmaceuticals Q1 net loss decreases

Threshold Pharmaceuticals, Inc., a biotechnology company, has reported that net loss for the first quarter ended March 31, 2013 was $9.21 million, or $0.16 loss per share, compared to a net loss of $115.53 million, or $2.30 loss per share, for the same ... [Published Individual.com - May 16 2013]

Entities: Threshold Pharmaceuticals Inc, Barry Selick, Siemens Healthcare, Hypoxia

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences

A live webcast of each presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of each presentation will be archived on the site for 30 days.About Threshold Pharmaceuticals Threshold Pharmaceuticals, ... [Published Stockwatch - May 09 2013]

Entities: Threshold Pharmaceuticals Inc, Clinical trials, Tumor, Drugs

First reported May 07 2013 - Updated May 07 2013 - 2 reports

Threshold Pharmaceuticals Has Returned 22.6% Since SmarTrend Recommendation (THLD)

SmarTrend identified a Downtrend for Threshold Pharmaceuticals (NASDAQ:THLD) on September 17th, 2012 at $6.51. In approximately 8 months, Threshold Pharmaceuticals has returned 22.60% as of today's recent price of $5.04.In the past 52 weeks, Threshold ... [Published Comtex SmarTrend - May 07 2013]

Entities: Threshold Pharmaceuticals Inc, watchlist, Therapeutics, Metabolism

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Piper Jaffray Companies

Threshold Pharma (THLD) Posts Quarterly Results

Threshold Pharma (NASDAQ: THLD) released its earnings data on Thursday. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.09) by $0.07, StockRatingsNetwork reports. The company had revenue of $2.90 ... [Published American Banking News - Earnings - May 02 2013]

Entities: Threshold Pharmaceuticals Inc, Solid Tumors, Piper Jaffray Companies

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Threshold Pharmaceuticals (THLD) Posts Q1 Loss of 16c/Share

Threshold Pharmaceuticals (NASDAQ: THLD) reported Q1 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.8 million.For earnings history and earnings-related ... [Published Street Insider - May 02 2013]

Entities: Threshold Pharmaceuticals Inc, iPad, iPhone

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) Long-Term Investor Alert: Investigation announced

- SAN DIEGO -- An investigation on behalf of investors in shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) was announced concerning whether certain Threshold Pharmaceuticals officers and directors possibly breached their fiduciary duties in connection ... [Published Prlog - May 01 2013]

Entities: Threshold Pharmaceuticals Inc, Fiduciary, Investigation, Total Revenue

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Threshold Pharmaceuticals Down 22.9% Since SmarTrend Downtrend Call (THLD)

(Comtex SmarTrend(R)) SmarTrend identified a Downtrend for Threshold Pharmaceuticals (NASDAQ:THLD) on September 17th, 2012 at $6.51. In approximately 7 months, Threshold Pharmaceuticals has returned 22.89% as of today's recent price of $5.02. Thres ... [Published Individual.com - Apr 25 2013]

Entities: Threshold Pharmaceuticals Inc, Comtex

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Threshold Pharmaceuticals Announces Presentation and Webcast at the 12th Annual Needham Healthcare Conference

A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com. A replay of the presentations will be archived on the site for 30 days.About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. ... [Published Stockwatch - Apr 25 2013]

Entities: Threshold Pharmaceuticals Inc, Healthcare Conference, Clinical trials, Tumor, Drugs

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Threshold: My Biotech Pick Of The Year

ByEquity Options Guru: It can be a difficult process to try and identify the best stocks in the biotechnology world. Each biotech claims to have perfected its relevant science and investors need to look past that and actually decide which ones are contenders ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 23 2013]

Entities: Threshold Pharmaceuticals Inc, Biotechnology, Hypoxia, Therapeutics, Tumor

Quotes

...our acquisition of an investigational hypoxia PET imaging agent, [18F]-HX4, from Siemens Healthcare," said Barry Selick, Ph D , CEO of Threshold. "We remain focused on clinical execution of ongoing studies of TH-302 and identifying additional development opportunities and regulatory pathways that could lead to approval of TH-302 in new indications."

Threshold Pharmaceuticals Q1 net loss decreases [Published Individual.com - May 16 2013]

...Delivered subcutaneously, sirukumab is a monoclonal antibody targeting the cytokine interleukin ( "-6. showed that at week 12, an improvement in ACR20 greater than 20% was seen in 75% of the sirukumab group versus 21% in the placebo group (p=.002). Considering CCX354's promising efficacy, selectivity, and oral administration, it's puzzling why GSK has not yet advanced CCX354."

Upcoming Catalysts Could Push ChemoCentryx To Double In 2013 [Published Seeking Alpha - May 10 2013]

...in oncology, which we believe will bring an appropriate perspective for Ambit at this stage," said Michael Martino, President and CEO of Ambit. "We look forward to his contributions toward the development of quizartinib and the rest of our pipeline."

Ambit Biosciences Appoints to Board of Directors [Published BioSpace - Apr 15 2013]

...therapeutics carries potential to improve patient care," said Britta Fuenfstueck, chief executive officer, Siemens Healthcare Molecular Imaging. "Siemens PETNET Solutions will continue to provide technical expertise and resources to support Threshold development and potentially commercialize this tracer through its worldwide network of best-in-class radiopharmaceutical manufacturing and distribution facilities."

Threshold to acquire hypoxia PET imaging agent [18F]HX4 from Siemens [Published PharmaBiz - Mar 23 2013]

More Content

sort by: Date \| Relevance
Threshold Pharmaceuticals Earnings Review: 17 D... [Published Individual.com - May 20 2013]
Earnings Look Back: Threshold Pharmaceuticals I... [Published Individual.com - May 18 2013]
A Journey To Add Biotech To The Portfolio [Published Seeking Alpha - May 18 2013]
Threshold Pharmaceuticals Shares Climbing Highe... [Published Individual.com - May 17 2013]
Threshold Pharmaceuticals Inc. Files SEC Form 1... [Published NewsRX - May 17 2013]
Threshold Pharmaceuticals Q1 net loss decreases [Published Individual.com - May 16 2013]
Buyers Accumulate Shares of Threshold Pharmaceu... [Published Individual.com - May 10 2013]
Upcoming Catalysts Could Push ChemoCentryx To D... [Published Seeking Alpha - May 10 2013]
Threshold Pharmaceuticals Announces Presentatio... [Published Stockwatch - May 09 2013]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - May 09 2013]
Threshold Pharmaceuticals Has Returned 22.6% Si... [Published Comtex SmarTrend - May 07 2013]
Threshold Pharmaceuticals Has Returned 22.6% Si... [Published Individual.com - May 07 2013]
New Market Report: Sarcomas - Pipeline Review, ... [Published Live-PR.com - May 05 2013]
Threshold Pharma (THLD) Posts Quarterly Results [Published American Banking News - Earnings - May 02 2013]
Market Report, "Neuroendocrine Tumors - Pipelin... [Published Live-PR.com - May 02 2013]
Are These The Biotech Stars Of Tomorrow? [Published Nasdaq - May 02 2013]
Threshold Pharmaceuticals (THLD): Q1 EPS of -$0... [Published Seeking Alpha - May 02 2013]
Threshold Pharmaceuticals (THLD) Posts Q1 Loss ... [Published Street Insider - May 02 2013]
Threshold Pharmaceuticals Reports First Quarter... [Published Marketwire - Breaking News Releases - May 02 2013]
8-K - THRESHOLD PHARMACEUTICALS INC (0001183765... [Published SEC Filings - May 02 2013]
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) L... [Published Prlog - May 01 2013]
Agenus 8 Near term Data Drivers with a Market O... [Published BioMedReports - Apr 29 2013]
Clinical-stage pharmaceutical company Scioderm ... [Published AltAssets.net - Apr 29 2013]
New market study, "Sarcomas - Pipeline Review, ... [Published Live-PR.com - Apr 27 2013]
Scioderm Closes $16 Million in Series A Financing [Published PE Hub News - Apr 27 2013]
Threshold Pharmaceuticals Down 22.9% Since Smar... [Published Individual.com - Apr 25 2013]
Threshold Pharmaceuticals Announces Presentatio... [Published Stockwatch - Apr 25 2013]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Apr 25 2013]
Threshold: My Biotech Pick Of The Year [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 23 2013]
Research and Markets: Refractory Multiple Myelo... [Published Business Wire - Apr 18 2013]

Blogs

sort by: Date \| Relevance
IPOs, Lawsuits, and Cancer Treatments: Healthca... [Published Wall St. Cheat Sheet - Jan 25 2013] Healthcare stocks ended the generally positive week on an upswing, with shares of Threshold Pharmaceuticals starting the day up more than 9 percent. But shares of LipoScience, which began their first day of trading on the Nasdaq Friday morning, took ...
IBM Dubbed Analyst Favorite and 4 Stock Analyse... [Published Wall St. Cheat Sheet - Jan 23 2013] Cree Inc. ( NASDAQ:CREE ): Current Price: $39.84 Stifel Nicolaus has increased its target on Cree following the company’s report of stronger Q2 results than predicted. The firm believes that the company’s margins will keep rising, and it keeps its ...

Press Releases

sort by: Date \| Relevance
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - May 09 2013]
Threshold Pharmaceuticals Reports First Quarter... [Published Marketwire - Breaking News Releases - May 02 2013]
Threshold Pharmaceuticals Announces Presentatio... [Published Marketwire - Breaking News Releases - Apr 25 2013]
Research and Markets: Refractory Multiple Myelo... [Published Business Wire - Apr 18 2013]
SHAREHOLDER ALERT: The Law Firm of Levi & Korsi... [Published Financial Services - Apr 03 2013]